Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy
| Title: | Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy |
|---|---|
| Authors: | Anna Gueiderikh, Jérémy Baude, David Baron, Renaud Schiappa, Sandrine Katsahian, Damien Moreau, Marc Laurans, Jean-Emmanuel Bibault, Sarah Kreps, Pierre-Yves Bondiau, Magali Quivrin, Alexis Lépinoy, David Pasquier, Jean-Michel Hannoun-Levi, Philippe Giraud |
| Source: | Frontiers in Oncology, Vol 14 (2024) |
| Publisher Information: | Frontiers Media S.A., 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | nodal recurrence, prostate adenocarcinoma, whole pelvic radiation therapy, SBRT (stereotactic body radiation therapy), androgen deprivation therapy (ADT), PSA doubling time, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | BackgroundNodes are the second site for prostate cancer recurrence. Whole-pelvic radiotherapy (WPRT) has shown superiority over nodal stereotactic body radiotherapy (SBRT) in two retrospective cohorts. We aimed to compare both modalities and assess factors associated with treatment outcomes.Materials and methodsThis retrospective multicentric cohort study included patients from five institutions spanning from 2010 to 2022. Patients had a history of prostatic adenocarcinoma classified as N0 M0 at diagnosis with a first nodal-only pelvic castration-sensitive recurrence. Failure-free survival (FFS) was defined as the time from the end of RT to the first failure event–biochemical or imaging recurrence, or death.ResultsA total of 147 patients (pts) were analyzed, mainly treated for a recurrence after initial prostatectomy (87%), with 64 (43.5%) undergoing SBRT and 83 (56.5%) undergoing WPRT. SBRT was chosen mainly for dosimetric constraints (67%) and was associated with a lower rate of concomitant androgen deprivation therapy (ADT) prescription. With a median follow-up of 68 months [inter-quartile range (IQR) = 51], FFS was significantly lower in the SBRT group (p < 0.0001). In multivariable analysis, WPRT and ADT were associated with a longer FFS. Factors associated with a longer FFS after SBRT included associated ADT, lower prostate-specific antigen (PSA) levels, a PSA doubling time >6 months, and a Gleason score |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2234-943X 17752833 |
| Relation: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1468248/full; https://doaj.org/toc/2234-943X |
| DOI: | 10.3389/fonc.2024.1468248 |
| Access URL: | https://doaj.org/article/09d0d3c509a740dfbe17752833486e99 |
| Accession Number: | edsdoj.09d0d3c509a740dfbe17752833486e99 |
| Database: | Directory of Open Access Journals |
| ISSN: | 2234943X 17752833 |
|---|---|
| DOI: | 10.3389/fonc.2024.1468248 |
| Published in: | Frontiers in Oncology |
| Language: | English |